The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Understanding The Pathophysiology Of Schizophrenia, Major Depressive Disorder And Bipolar Disorder As A Basis For Improving Treatments
Funder
National Health and Medical Research Council
Funding Amount
$804,106.00
Summary
The Applicant seeks to understand the causes of the schizophrenia, bipolar disorder and major depressive disorder, which affect over 20% of the Australian population. This research is important as drug design, based on chemical remodelling, has not significantly advanced initial breakthroughs in treating psychiatric disorders and there is now a widespread belief that new drugs will only come from understand their causes.
Inhibitory Neurotransmitter Receptors As Therapeutic Targets For Chronic Pain And Anxiety Disorders
Funder
National Health and Medical Research Council
Funding Amount
$763,409.00
Summary
There are currently few effective long-term treatments for chronic pain and anxiety disorders. Here we propose to develop innovative therapies for both of these debilitating neurological disorders. In addition, we plan to improve our current understanding of how these disorders occur in the first place. This may identify novel potential therapeutic strategies for treating pain, anxiety and a host of other neurological disorders.
Molecular Characterisation Of Steroid Hormone-dependent Diseases Of The Cardiovascular And Reproductive Systems
Funder
National Health and Medical Research Council
Funding Amount
$1,085,790.00
Summary
Peter Fuller is both a molecular and clinical endocrinologist. His research examines steroid hormones in cardiovascular disease and cancer. The hormone aldosterone controls blood pressure and has a significant role in cardiac failure. This work will enable the development of tissue-specific blockers of aldosterone for the treatment of cardiovascular disease. Steroid hormones also have a role in granulosa cell tumours of the ovary and breast cancer; new insights will lead to novel therapeutics.
Pattern Recognition Receptors In Inflammation And Infection
Funder
National Health and Medical Research Council
Funding Amount
$622,655.00
Summary
Innate immunity provides our first line of defence against infections, but pathogens can overcome this system. Understanding how microbes disable innate immunity can teach us how to prevent and/or treat infectious diseases. Innate immunity acts by initiating inflammation. Many important acute and chronic diseases develop when this process is dysregulated. Blocking innate immunity thus has potential to treat many diseases. This project aims to understand innate immunity in these contexts.
Determining recurrence risk in breast cancer is crucial, as more than half of all recurrences occur after 5 years. However, optimal management of breast cancer is hampered by the challenges in finding rational preventative and predictive targets. Our vision is to find targets responsible for progenitor cell expansion, as candidates for prevention, and to find markers of relapse, to predict early versus late responders to therapy.
Hepatitis C virus (HCV) and Human immunodeficiency virus (HIV) infect 200 million and 50 million people world-wide, respectively, and there are no preventative vaccines. The work outlined in this fellowship seeks to understand the structure and function of the major surface proteins of these viruses, their ability to be recognised by the immune system and to develop a novel vaccine for the prevention of HCV.
Integrated Approaches To Targeting G Protein-coupled Receptors: Translational Studies Of Novel Drug-receptor Paradigms
Funder
National Health and Medical Research Council
Funding Amount
$851,980.00
Summary
This Fellowship focuses on one of the largest family of proteins found in the human body, the so-called ‘G protein-coupled receptors ‘ (GPCRs). GPCRs control how each of our cells communicates with one another, and have been implicated in virtually all diseases. This proposal will study new mechanisms of targeting drugs to GPCRs that can overcome current drug discovery bottlenecks and lead to new ways of treating neuropsychiatric, cardiovascular, inflammatory and metabolic diseases.
Research Fellowship: Understanding G Protein-coupled Receptors (GPCRs)
Funder
National Health and Medical Research Council
Funding Amount
$444,177.00
Summary
This project focuses on drug action at G protein-coupled receptors (GPCRs), the largest class of drug targets. It builds on key discoveries by the applicant that novel sites on GPCRs can be targeted by small molecules in a selective manner, thus minimizing side effects and maximizing therapeutic efficacy. Because this approach can work across most GPCR families, the relevance to the pharmaceutical industry and GPCR-related diseases, such as schizophrenia and diabetes, is very high.
Modulating Protein-Protein Interactions In Disease
Funder
National Health and Medical Research Council
Funding Amount
$863,910.00
Summary
Most diseases are driven by protein-protein interactions often with few/no greasy pockets to fit small molecule drugs. Innovative approaches to new drugs are needed for these proteins. This project combines chemistry, biochemistry and pharmacology to create new drug leads, new knowledge on drug action and disease development at gene, protein, cell, animal levels, and aims to trial new drug leads in preclinical and eventually clinical tests in inflammatory and metabolic diseases, pain and cancer.
The nuclear hormone receptors (NRs) translate hormonal, metabolic & pathophysiological signals into gene regulation, and several NRs are very important in human health. NRs are important therapeutics targets in the treatment of dyslipidemia, insulin insensitivity and breast cancer. Our data identifies new and novel NR targets that can be therapeutically/pharmacologically exploited in the context of exercise capacity, metabolic disease and breast cancer.